Results 111 to 120 of about 2,022,996 (246)

Figure 4 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors

<p>Pan-cancer correlation analysis of per-sample SA with nonsilent mutations in splicing machinery coding genes. Distribution of SA per sample, averaged across genes, by mutations in the splicing factor gene SF3B1 in BRCA (<b>A</b>) or HNSC (<b>B</b>). *, <i>P</i> value ≤ 0.05.
Ludmila Danilova, Elana J. Fertig, Daria A. Gaykalova, Rachel Karchin, Valsamo Anagnostou, Alexander V. Favorov, Elizabeth M. Jaffee, Nilofer S. Azad, Jessica Gore, Ali M. Saeed, Tamara Y. Lopez-Vidal, Neeha Zaidi, Mark Yarchoan, Archana Balan, Xiaoshan M. Shao, Michael D. Kessler, Theron Palmer   +16 more
openaire   +1 more source

Targeting Antigen‐Presenting Cells to Enhance the Tumor‐Spleen Immunity Cycle through Liposome‐Neoantigen Vaccine

Effective immune responses in both the spleen and the tumor microenvironment are crucial for cancer immunotherapy. However, delivery of neoantigen peptide vaccines to antigen‐presenting cells (APCs) at these sites remains challenging.
Chenxi Zhou, Feng Wang, JianPing Liao, Da Zhang, Yue Huang, Chenyi Wu, Shiyang Jiang, Zishi Kang, Xiaolong Liu, Ruihua Xu, Yu Xu, Bing‐Chen Wu, Bing Wang   +12 more
core   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer

Experimental Hematology & Oncology
Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to chemotherapy. However, PDAC with germline BRCA mutations, which lead to homologous recombination (HR) deficiency (HRD), demonstrated an increased sensitivity to platinum-based chemotherapy ...
Mengyue Lei, Jessica Gai, Thomas J. McPhaul, Huijuan Luo, Penghui Lin, Dongbing Liu, Michael Pishvaian, Nicholas J. Roberts, Kui Wu, Jin He, Lei Zheng   +10 more
doaj   +1 more source

Exceptional Response to Radiation Therapy for Cervical Cancers is Associated with Higher Predicted Tumor Neoantigen Burden and Selective Loss of Neoantigens [PDF]

International Journal of Radiation Oncology*Biology*Physics, 2019
L.E. Colbert, T. Karpinets, J. Zhang, A. Y. Delgado Medrano, T. Sims, T. Solley, A. Mitra, K. Court, G. Biegert, P.J. Eifel, A. Jhingran, L.L. Lin, L. Ramondetta, P.A. Futreal, M. Frumovitz, K. Schmeler, G. Matthew, S.M. Hahn, A.H. Klopp   +18 more
openaire   +1 more source

Figure 3 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors

<p>SA by tissue type and in relation to the tumor mutational burden. <b>A,</b> The SA averaged across genes per sample for tumor and normal samples for each tumor type analyzed (Wilcoxon test, Cohens <i>d</i>). <b>B,</b> The SA averaged across all genes per sample for TMB=high and TMB-low samples for all ...
Ludmila Danilova, Elana J. Fertig, Daria A. Gaykalova, Rachel Karchin, Valsamo Anagnostou, Alexander V. Favorov, Elizabeth M. Jaffee, Nilofer S. Azad, Jessica Gore, Ali M. Saeed, Tamara Y. Lopez-Vidal, Neeha Zaidi, Mark Yarchoan, Archana Balan, Xiaoshan M. Shao, Michael D. Kessler, Theron Palmer   +16 more
openaire   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

SY10-2 Neoantigenic potential of chromosomal rearrangements, and effects of filtering on tumor mutation burden estimates [PDF]

Annals of Oncology, 2021
openaire   +1 more source

Machine Learning‐Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma

Cancer Science, EarlyView.
An immune‐related 12‐gene signature developed through integrative machine learning stratified overall survival across multiple myeloma cohorts and remained independently associated with outcome. Single‐cell, somatic mutation, and transcriptome‐based drug‐response analyses further linked the signature to multicellular bone marrow context, distinct ...
Kai Wang, Chenfei Zhao, Jingru Shi, Shiwei Liu, Yi Chen, Jujuan Wang, Zhengxu Sun, Sanmei Wang, Lei Fan, Jin Fan, Xiaoyan Qu   +10 more
wiley   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source